In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
News|Podcasts|February 17, 2026
ACT Brief: AI Moves Into Implementation, Digital Measurement Adoption Accelerates, and Global Trial Competition Intensifies
Author(s)Andy Studna, Senior Editor
In today’s ACT Brief, we examine how AI is shifting from pilot programs into daily development workflows, how a new adoption platform is helping sponsors integrate digital measurement tools, and how global competition and data-driven site selection are reshaping clinical trial activity.
This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.
- In a video
interview with ACT, Angela Zubel of Debiopharm said 2026 is shaping up to be an implementation year as companies move beyond pilot programs and begin embedding AI and digital tools into routine drug development workflows. She noted that solutions once confined to experimentation are increasingly becoming part of daily operations across clinical development. Zubel added that broader deployment will mark a shift from testing AI’s potential to relying on it in execution. - The Digital Medicine Society has
launched the sDHT Adoption Navigator, a centralized platform designed to help sponsors integrate sensor-based digital health technologies into clinical trials. Developed with FDA funding, the resource consolidates regulatory guidance, validation standards, and implementation best practices into a single location. The platform also includes an AI-enabled research assistant to help teams identify relevant regulatory and scientific materials more efficiently. - In a new Pharm Exec
Q&A , Phesi CEO Gen Li said oncology remains the most studied area globally, while competition for investigator sites continues to intensify. He noted that data-driven site selection is helping sponsors identify high-performing but underutilized locations beyond the most established research centers. Li added that China is emerging as the fastest-growing clinical trial market, reflecting ongoing expansion in global development capacity.
That’s all for today’s ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.
Related to this article
In today’s ACT Brief, we examine how AI is moving into continuous clinical operating models, how trust is built into oncology real-world evidence, and how the FDA approved a self-administered option for thyroid eye disease.
In today’s ACT Brief, we examine who decides what trials measure, how designing for human thinking improves site execution, and how the FDA extended an immunotherapy to a new bladder cancer population.
In Episode 3 of The Human Side of Clinical Trials, hosts Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., speak with Jason Riis, PhD, CEO and chief behavioral scientist at Behavioralize, about why a well-written protocol doesn’t always translate into consistent execution, and how designing for the way people actually think and learn can reduce site burden and the need for costly unlearning.
In today’s ACT Brief, we examine what it will take to scale EHR-to-EDC connections for real-time trials, how the FDA is reimagining rare disease drug development, and why oncology real-world evidence still faces persistent data barriers.
In today's ACT Brief, we examine how representation gaps in trials are shaped by structural design decisions, how new partnerships automate data transfer from site systems to sponsor platforms, and how Roche is licensing a novel obesity target from a biotech pioneer.
Aardvark released exploratory data from its stopped Phase 3 HERO trial in Prader-Willi syndrome after FDA lifted the hold, and plans a redesigned Phase 3.
Clinical trials capture data faster than ever, but the real bottleneck is the distance between data capture and a decision teams can trust.
Trending on Applied Clinical Trials Online
1
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
2
Where AI Governance in Clinical Development Falls Short
3
ACT Brief: Orchestrated AI Clinical Environments, eSource Coordinator Satisfaction, and Faster Clinical Trials Act
4
Clinical Trials Do Not Have a Data Problem, They Have a Decision-Readiness Problem
5